ARLINGTON, Virginia
,
September 8, 2023
(press release)
–
Today, the American Diabetes Association® (ADA) sent a letter to congressional leadership urging action on legislation to increase transparency in prescription drug rebates and prevent pharmacy benefit manager (PBM) practices from inflating the cost of prescription drugs. “Drug middlemen function at the center of the pharmaceutical supply chain and have virtually unparalleled power to affect drug costs, acting as intermediaries between insurers, manufacturers, and pharmacies,” according to the letter. Drug manufacturers often pay PBMs rebates on their drugs in exchange for coverage, limiting patient access to other therapies and driving up the list price of available drugs. The letter asks congressional leadership to consider a number of proposals as part of a PBM reform package, including: The House and Senate have been working on bipartisan drug pricing legislation this year that would reduce the cost of insulin and other prescription drugs, namely by reforming the prescription drug rebate system and improving price transparency across the health care system. # # #
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.